Top 10 Healthcare Technology Companies To Own In Right Now

Top 10 Healthcare Technology Companies To Own In Right Now: InterMune Inc.(ITMN)

InterMune, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies in pulmonology and fibrotic diseases. In pulmonology, the company focuses on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It markets pirfenidone, an orally active drug that inhibits the synthesis of TGF-beta under the Esbriet name in the European Union, as well as in a Phase III clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the Pirespa trade name. The company?s research programs focus on the discovery of small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. InterMune, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of InterMune (NASDAQ: ITMN) got a boost, shooting up 14.31 percent to $39.22 after the company presented Phase 3 ASCEND study of Pirfenidone in idiopathic pulmonary fibrosis. Leerink upgraded the stock from Market Perform to Outperform.

• [By Jake L'Ecuyer]

  Shares of InterMune (NASDAQ: ITMN) got a boost, shooting up 13.90 percent to $39.07 after the company presented Phase 3 ASCEND study of Pirfenidone in idiopathic pulmonary fibrosis. Leerink upgraded the stock from Market Perform to Outperform.

• [By Roberto Pedone]

   

  InterMune (ITMN), a biotechnology company, focuses on the research, development, and commercialization of therapies for pulmonology and orphan fibrotic diseases in North America and Europe. This stock closed up 13.4% at $38.92 in Monday's trading session.

   

  Monday's Volume: 11.92 million
  
  Three-Month Average Volume: 3.56 million
  
  Volume % Change: 350%

  &! nbsp;

  From a technical perspective, ITMN gapped sharply higher here right above its 50-day moving average of $32.38 with heavy upside volume. This monster spike higher on Monday pushed shares of ITMN into breakout and 52-week-high territory, since the stock took out some near-term overhead resistance levels at $36.71 to its former 52-week high of $38.73. Market players should now look for a continuation move to the upside in the short-term if ITMN manages to clear Monday's intraday high of $39.90 with strong volume.

   

  Traders should now look for long-biased trades in ITMN as long as it's trending above $37 or above Monday's low of $35.85 and then once it sustains a move or close above $39.90 with volume that this near or above 3.56 million shares. If that move starts soon, then ITMN will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $45 to $50.

   

• [By Lee Jackson]

  InterMune Inc. (NASDAQ: ITMN) continues to soar on the strength of global sales of its top drug Esbriet. The company is still seeking FDA approval to sell Esbriet in the United States. Before approval can take place, the company is awaiting top-line results from the phase 3 ASCEND study. InterMune expects to release these results during the second quarter of 2014. This could be a huge catalyst. UBS has a $15 price target, which should rise soon, and the consensus is at $16.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-10-healthcare-technology-companies-to-own-in-right-now.html